This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
LONDON & HOUSTON--(BUSINESS WIRE)--Jul. 18, 2018-- Baker Hughes, a GE company (NYSE: BHGE) today announced an agreement to sell its Natural Gas Solutions (NGS) business to two separate entities, First Reserveand Pietro Fiorentini S.p.A., for a combined value of $375 million. NGS is part of BHGE's Turbomachinery & Process Solutions (TPS) segment, providing commercial and industrial products such as gas meters, chemical injection pumps, pipeline repair products and electric actuators.
General Electric Company (GE - Free Report) is scheduled to report second-quarter 2018 results on Jul 20, before the market opens. This industrial conglomerate’s financial performance in the last four quarters was mixed, having recorded better-than-expected results in two and lagging estimates in the other two. The company’s average earnings surprise was a positive 3.27%. In the last reported quarter, the company’s earnings of 16 cents per share surpassed the Zacks Consensus Estimate of 11 cents by 45.
HON BHI HD GEC GE WAB HON GGG BHGE GNE
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH
HOUSTON & LONDON--(BUSINESS WIRE)--Jul. 9, 2018-- Baker Hughes, a GE company (NYSE:BHGE) announced today that the Baker Hughes international rig count for June 2018 was 959, down 8 from the 967 counted in May 2018, and down 1 from the 960 counted in June 2017. The international offshore rig count for June 2018 was 195, down 3 from the 198 counted in May 2018, and down 2 from the 197 counted in June 2017.
The portfolio has underperformed its benchmark so far in 2018, with General Electric being a significant contributor, but it is properly positioned to benefit from several major trends.
FB TWX UAA MET KEY BAC TWTR AAPL ACN INOTF CAH INTC BAC GEC GE C ITT BHGE SYF TWC UA BHI TGT GNE
Editor's note: Seeking Alpha is proud to welcome Benen Ling as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
GE GEC ARII WFT BHGE GNE AOMFF UTX ALSMY ALO
A McDermott International, Inc. (MDR - Free Report) -led consortium, which includes Baker Hughes, a GE company (BHGE - Free Report) , recently received a contract from the South Korean company, POSCO DAEWOO Corp. for developing the Shwe gas field, offshore Myanmar. The consortium will help POSCO with the second phase of the development program for the field located off the coast of Western Myanmar.
BHI DK GM.WS.A GM.WS.B BHGE GM.WS.C MDR GM GM.WSB CEO
Now that General Electric (NYSE:GE) announced it is breaking up, speculators are kicking the tires to value the pieces. This sent GE stock up $1 per share on June 26, which doesn’t sound like much but represented an 8% pop in shares that open for trade June 27 at about $13.80 each.
BHI GE GEC BHGE GNE ATHN
U.S. stock futures are hovering just above break even this morning. Wall Street bears are taking a break from selling to reassess the current trade situation. The lull comes, in part, after President Trump backed away from banning Chinese investment in U.S. tech firms. However, many analysts believe the U.S.-China trade war could flare up considerably at any time.
BHI FB GE GEC T ATH TWX BHGE GNE TWC
McDermott International, Inc. (NYSE: MDR) and Baker Hughes, a GE company (NYSE: BHGE), have announced the award of a contract by POSCO DAEWOO Corp. for phase two of the Shwe gas field development offshore Western Myanmar.
BHI BHGE MDR MCDFF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET